Introduction {#S1}
============

Acute hemorrhagic encephalomyelitis (AHEM) or acute hemorrhagic leukoencephalitis is considered a rare and extremely severe form of acute disseminated encephalomyelitis (ADEM). AHEM is characterized by an acute and rapidly progressive encephalopathy including hemorrhagic necrosis of the parenchyma of the central nervous system. It is usually fatal ([@B1]--[@B3]). Many treatment options have been used including intravenous (IV) steroids, intravenous immunoglobulins (IVIG), and plasmapheresis ([@B4]). There have been few reports of survival following early intervention with high-dose corticosteroid therapy and/or decompressive craniotomy ([@B5]--[@B9]).

RANBP2, a nuclear pore protein, has numerous roles in the cell cycle. RANBP2 is associated with microtubules and mitochondria suggesting roles in intracellular protein trafficking or energy maintenance and homeostasis of neuronal cells. RANBP2 mutations have been reported in acute necrotizing encephalopathy (ANE) which could present with coma, convulsions, and encephalopathy. The hallmark of ANE is multiple, symmetric brain lesions located in the thalami bilaterally, putamina, deep periventricular white matter, cerebellum, and brainstem. It could be triggered by a viral infection in previously healthy children ([@B10]).

We report a new case of AHEM associated to a Ran Binding Protein (*RANBP*)-2 variant and responsive to combined craniectomy, intravenous methylprednisolone (IVMP), and IVIG as inaugural manifestation of multisystemic autoimmunity in a girl with sickle cell disease (SCD).

Case Report {#S2}
===========

A 6-year-old girl known for SCD treated on folic acid and hydroxyurea was admitted for new-onset diplopia \[day 0 (D0): refers to the start of the diplopia\] 6 weeks after respiratory tract infection due to rhinovirus. She was diagnosed with a fourth nerve palsy secondary to an acquired demyelinating syndrome. The initial brain magnetic resonance imaging (MRI) performed at D5 after onset of neurological symptom showed left midbrain and pontine edema with expansion of the brainstem, right caudate nucleus, and scattered supratentorial white matter foci of high T2/FLAIR signal (Figure [1](#F1){ref-type="fig"}). Brain MR angiography (MRA) showed a normal appearing circle of Willis. The cerebrospinal fluid (CSF) obtained by lumber puncture was normal (WBC 1 cells/μl, RBC 0 cells/μl, glucose 2.9 mmol/L, protein 0.18 g/L, and absent oligoclonal bands). The infectious workup including blood bacterial culture, CSF bacterial and viral cultures, nasopharyngeal aspirate (tested for Influenza A, Influenza B, Parainfluenza 1-2-3, Respiratory Syncytial Virus, Adenovirus, Coronavirus 229E, Coronavirus OC43, Metapneumovirus, Enterovirus, and Rhinovirus), and serologies for Epstein--Barr virus, *Mycoplasma pneumoniae*, HTLV I, HTLV II, HIV1, and Lyme disease were negative. Bartonella Henselae IgG was positive (1:1,280) reflecting a previously acquired common and self-limited infection in our area. Antinuclear antibodies (ANA) were positive (1:160). B12 and folate levels were normal. Smooth muscle antibodies were negative. Anti-mitochondrial antibodies were positive. Sedimentation rate was 65 mm/h. She was treated with five doses of IVMP (30 mg/kg/day) followed by 9 days of oral prednisone (1 mg/kg/day). At discharge, her neurological exam was significant only for vertical diplopia.

![Brain magnetic resonance imaging on first presentation (day 5) showing multiple areas of abnormal signals (white arrowheads): left midbrain high signal on FLAIR sequence **(A)**, left midbrain hypersignal on T2 weighed (T2W) sequence **(B)**, central gadolinium enhancement of left midbrain lesion on T1 sequence **(C)**, and scattered supratentorial white matter foci of high FLAIR signal **(D)**.](fneur-09-00130-g001){#F1}

She presented 1 month later with 5 days of upper respiratory tract infection symptoms, fever, headache, and a rapidly progressive right-hand weakness (D30) with normal alertness. She had normal blood pressure (120/81 mmHg). She was started on cefotaxime, vancomycin, and acyclovir. White cell count was 13.4 × 10^9^/L, hemoglobin was 7.8 g/L, and platelets were 239 × 10^9^/L. While in the MRI machine (D30) she deteriorated with vomiting and reduced level of consciousness (Glasgow Coma Scale dropped from 15 to 8 over 30 min). Brain MRI showed a rapid progression over a few sequences of an active bleed involving both superficial and deep gray matter as well as subcortical white matter of the left hemisphere anterior quadrant. Brain MRA was normal (Figures [2](#F2){ref-type="fig"}A--F). The patient was immediately brought out of the magnet and her physical exam demonstrated unequal dilated pupils. She received IV mannitol and hypertonic saline for the management of acute intracranial hypertension/herniation and was taken for surgery. She underwent left frontotemporoparietal decompressive craniotomy, evacuation of left frontoparietal intracerebral hemorrhage, and insertion of an external ventricular drain (EVD). Upon opening the skull, there was significant dural tension, and on opening the dura mater, there was a large amount of bleeding, in addition to brain swelling and necrosis. Estimated blood loss was 3.5 L. She received 8 units of packed red blood cells, 3 units of cryoprecipitate, 6 units of fresh frozen plasma, and 3 units of platelets. Coagulation profile showed international normalization ratio = 3.38, prothrombin time = 51.2 s, and partial thromboplastin time = 122 s. An intraventricular pressure monitor was inserted. She returned with stable vitals to PICU. At D31, the CT scan showed extensive multi-compartmental bleed involving the left frontoparietal lobes, the interhemispheric fissure, and the left hemispheric arachnoid spaces. New white matter lesions were detected in the left posterior parietal and occipital lobes and in the left caudate head. MRI at D33 showed interval worsening with disseminated gray and white matter non-hemorrhagic lesions in the right cerebral and both cerebellar hemispheres, bilateral deep gray nuclei, as well as new necrotic non-hemorrhagic lesions in the left hemisphere (Figures [2](#F2){ref-type="fig"}G--I). She was started on IVMP (30 mg/kg/day for 5 days) and IVIG (1 g/kg/day for 2 days). Repeat MRI at D9 showed no new parenchymal hemorrhage and partial resolution of the non-hemorrhagic lesions (Figure [3](#F3){ref-type="fig"}). Prednisolone was tapered course over 6 weeks. At discharge (D71), she was able to say a few words and had better power of her right side. Brain MRI performed 3 months later showed complete resolution of the non-hemorrhagic non-necrotic lesions, mainly seen in the right cerebral hemisphere and the cerebellum.

![Brain magnetic resonance imaging (MRI) (day 30) at the time of the relapse of the neurological manifestations showing left frontoparietal cortical and subcortical areas of isointense T1, high T2 **(A)**, FLAIR **(B)**, and restricted diffusion **(C)** signals (arrowhead) increasing in size along the MRI examination, due to an active hyperacute bleed \[arrow **(A)** pointing at spot sign indicating active bleed\]. Area of high T2 and FLAIR signal changes (arrowheads) in the head of the caudate nucleus **(D)** and of abnormal diffusion weighed images (DWI) in the subcortical right cerebellar white matter (arrowheads) **(E)**. Previous left midbrain lesion has resolved with only a tiny residual of high FLAIR signal corresponding to minimal residual gliosis (arrowhead) **(F)**. Follow-up brain MRI at D33 showing a necrotico-hemorrhagic lesion in the left hemisphere **(G,I)**, interval evolution of cortical/subcortical lesions, with new lesions in the bilateral thalami **(G)**, cerebellar hemispheres **(H)**, and right cerebral hemisphere **(I)** (arrowheads indicate abnormal signals).](fneur-09-00130-g002){#F2}

![FLAIR sequences of brain magnetic resonance imaging (MRI) at day 39 showing interval evolution and improvement of thalamic **(A)**, cerebellar **(B)**, and right cerebral hemispheric lesions **(C)** with no additional lesions as compared to the previous MRI (arrowheads indicate hypersignal abnormalities).](fneur-09-00130-g003){#F3}

Brain biopsy of the hematoma, some small vessels, cortex, and white matter showed necrotic area, reactive and non-specific findings which could be entirely explained by compressive changes adjacent to a hematoma. There was diffuse microglial activation and signs of early microinfarcts. Blood, CSF and urine culture, and PCR (HSV1/2) were negative for bacteria and for viruses. CSF obtained through craniotomy and EVD performed at D32 showed elevated proteins 2.56 g/L, glucose 3.6 mmol/L, white blood cells 9 cells/μL, and red blood cells 1,341 cells/μL. ANA and anti-DNA antibody were negative.

Anti-extractable nuclear antigens (SSA-RO, SSB-LA, smith, RNP) were negative. Serum autoimmune antibodies panel (NMO, NMDAR, AMPA I/II, GAB, MAG, VGCC, MOG, YO, HU, RI) were negative but GAD antibody was slightly positive, possibly due to the IVIG infusion. EBV showed no signs of recent infection.

After discharge, the patient was started on regular transfusion exchange. Six months later, the patient was diagnosed to have Crohn's disease and primary sclerosing cholangitis. Two years later, the patient still suffers right hemiparesis but is able to walk without support. She presents an expressive aphasia. Her intellectual abilities are average, or below the mean but in the normal range, except for the speed of information processing, verbal working memory, and some elaborated executive functions.

Genetic Tests {#S3}
=============

A gene panel (Table [1](#T1){ref-type="table"}) targeting inflammatory disorders and post-infectious necrotic encephalopathies found a heterozygous *RANBP2* missense mutation (NM_006267.4, c.4993A\>G, p.Lys1665Glu). This mutation has not been previously reported in the HGMD database. This variant has been observed at a frequency of \<0.01% across the entire Broad ExAC dataset of individuals without severe childhood onset disease (6/117,118 alleles). Analysis of amino acid conservation indicates that the wild-type amino acid Lys1665 is conserved in 59 of 60 mammals examined, including 12 of 12 primates, and in 25 of 34 non-mammalian vertebrates increasing the likelihood that a change at this position might not be tolerated. *In silico* tools predict that this variant is damaging (SIFT and Align GVGD).

###### 

List of the 45 genes associated with acute hemorrhagic encephalomyelitis/autoimmune inflammatory disorders studied in our patient.

  \#   Gene abbreviation   Gene full name                                       OMIM \#    \#       Gene abbreviation   Gene full name                                                OMIM\#
  ---- ------------------- ---------------------------------------------------- ---------- -------- ------------------- ------------------------------------------------------------- ------------
  1    AP1S3               ADAPTOR-RELATED PROTEIN COMPLEX 1, SIGMA-3 SUBUNIT   615781     24       MYOM2               MYOMESIN 2                                                    603509
  2    AQP1                AQUAPORIN 1                                          107776     25       NLRC4               NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 4           606831
  3    AQP4                AQUAPORIN 4                                          600308     26       NLRP12              NLR FAMILY, PYRIN DOMAIN-CONTAINING 12                        609648
  4    CARD14              CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 14     607211     27       NLRP3               NLR FAMILY, PYRIN DOMAIN-CONTAINING 3                         606416
  5    CD8A                CD8 ANTIGEN, ALPHA POLYPEPTIDE                       186910     28       NLRP7               NLR FAMILY, PYRIN DOMAIN-CONTAINING 7                         609661
  6    CECR1               CAT EYE SYNDROME CHROMOSOME REGION, CANDIDATE 1      607575     29       NOD2                NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN PROTEIN 2           605956
  7    ELANE               ELASTASE, NEUTROPHIL-EXPRESSED                       130130     30       NRP1                NEUROPILIN 1                                                  602069
  8    FASLG               FAS LIGAND                                           134638     31       OCLN                OCCLUDIN                                                      602876
  9    FLT1                FMS-RELATED TYROSINE KINASE 1                        165070     32       PDCD1               PROGRAMMED CELL DEATH 1                                       600244
  10   HAX1                HCLS1-ASSOCIATED PROTEIN X1                          605998     33       PLCG2               PHOSPHOLIPASE C, GAMMA-2                                      600220
  11   IL10                INTERLEUKIN 10                                       124092     34       PSMB8               PROTEASOME SUBUNIT, BETA-TYPE, 8                              177046
  12   IL10RA              INTERLEUKIN 10 RECEPTOR, ALPHA                       146933     35       PSTPIP1             PROLINE/SERINE/THREONINE PHOSPHATASE-INTERACTING PROTEIN 1    606347
  13   IL1RN               INTERLEUKIN 1 RECEPTOR ANTAGONIST                    147679     **36**   **RANBP2**          **RAN BINDING PROTEIN 2**                                     **601181**
  14   IL2                 INTERLEUKIN 2                                        147680     37       RBCK1               RANBP-TYPE AND C3HC4-TYPE ZINC FINGER-CONTAINING 1            610924
  15   IL36RN              INTERLEUKIN 36 RECEPTOR ANTAGONIST                   605507     38       RPS27A              RIBOSOMAL PROTEIN S27a                                        191343
  16   IRF1                INTERFERON REGULATORY FACTOR 1                       147575     39       SH3BP2              SH3 DOMAIN-BINDING PROTEIN 2                                  602104
  17   ITGA4               INTEGRIN, ALPHA-4                                    192975     40       SLC29A3             SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTER), MEMBER 3   612373
  18   KDR                 KINASE INSERT DOMAIN RECEPTOR                        191306     41       STAT1               SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1            600555
  19   LPIN2               LIPIN 2                                              605519     42       TMEM173             TRANSMEMBRANE PROTEIN 173                                     612374
  20   MBP                 MYELIN BASIC PROTEIN                                 15159430   43       TNFRSF11A           TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 11A        603499
  21   MEFV                FAMILIAL MEDITERRANEAN FEVER GENE                    608107     44       TNFRSF1A            TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 1A         191190
  22   MVK                 MEVALONATE KINASE                                    251170     45       VEGFA               VASCULAR ENDOTHELIAL GROWTH FACTOR A                          192240
  23   MX1                 MYXOVIRUS RESISTANCE 1                               147150                                                                                                

*Bold characters indicate gene in which potentially pathogenic variant was detected*.

Discussion {#S4}
==========

Several differential diagnoses of acute encephalopathy in a patient with sickle cell anemia can be considered. An infectious encephalitis, including herpes encephalitis, was ruled out by blood and CSF bacterial and viral cultures and negative HSV I/II PCR. Nasopharyngeal aspirate was negative for viruses. Some infections have been previously associated with necrotizing encephalitis such as Influenza A ([@B11]). SCD patients are prone to ischemic or hemorrhagic strokes ([@B12]). Primary hemorrhagic stroke is uncommon in pediatric SCD. Most cases were from adults and have been described in the context of previous ischemic stroke, aneurysms, low hemoglobin, acute chest syndrome, and hypertransfusions. Moreover, although hemorrhagic stroke has been described in SCD patients receiving transfusion or corticosteroids, it was in the context of elevated blood pressure which was not present in our case ([@B13]). This was ruled out as the MRI findings were not consistent with a specific vascular territory and normal arterial and venous flows were shown on vascular imaging. Another differential is posterior reversible encephalopathy syndrome which has been reported in SCD patients ([@B13]--[@B16]). However, it is unlikely in our case due to the severity of the brain injury and the absence of classic precipitating factors of posterior reversible encephalopathy syndrome such as high blood pressure. Macrophage activation syndrome could also lead to acute necrotic brain injury. However, it is associated to high ferritin and low triglycerides at the time of the encephalopathy, other multisystemic injuries, typical neuropathological findings, and recurrence over time, which were not noted in our patient ([@B17]). Parvovirus B19 has been described to cause encephalopathy in sickle cell patients. It is associated with aplastic anemia. It caused punctate areas of hemorrhages in the basal ganglia, periventricular white matter, and mainly along the posterior parietal cortex. This was attributed to parvovirus B19-induced vasculitis ([@B18]). In our patient, there was no sign of aplasia or any neuroradiological finding of parvovirus B19 infection. Finally, acute encephalitis has been observed in SCD patients in the context of arterial hypoxemia from fat embolism, pulmonary embolism, sudden anemia, or acute chest syndrome due to pneumonia ([@B19]). This was ruled out as the patient did not have clinical or radiological signs of acute chest syndrome or embolism and there was no arterial hypoxemia.

Acute hemorrhagic encephalomyelitis has been described in pediatric patients following ADEM or ADEM-like episodes ([@B20], [@B21]). AHEM is the most plausible diagnosis in our patients based on the clinical and radiological presentation, the preceding ADEM-like episode, and the exclusion of other etiologies of acute encephalopathy. Other patients with AHEM have been described in the SCD context ([@B7], [@B19]). Many treatment options have been used to treat AHEM; of these, IV steroids have been associated with survival following aggressive, high-dose corticosteroid therapy ([@B5]--[@B9], [@B22]--[@B25]).

Autosomal dominant mutations (with incomplete penetrance) in *RANBP2* have been associated with susceptibility to infection-induced necrotizing encephalopathy ([@B26], [@B27]). Previously healthy patients with pathogenic mutations in *RANBP2* can present acutely with encephalopathy and convulsions in the context of an infection, with brain imaging revealing involvement of the brainstem, thalami, putamina, cerebellum and external capsules, and claustrum ([@B10]). Our patient has a similar presentation and imaging features as infection-induced necrotizing encephalopathy, including bilateral thalamic involvement. The rare heterozygous previously unreported variant we identified in *RANBP2* affects a very conserved aminoacid and is predicted deleterious using *in silico* tools (a prediction tool performing a fast bioinformatics analysis which can predict the pathogenicity of a variant based on the change to an amino acid). It is possible that this variant is pathogenic and responsible for the clinical phenotype. There is an overlap between the diagnostic criteria of AHEM and those of acute hemorrhagic encephalopathy ([@B25], [@B26]) making possible that both entities might be part of the same pathophysiological continuum. *RANBP2* is a protein playing an important role in the energy homeostasis of neuronal cells ([@B28]). Hence, *RANBP2* dysfunction might make neuronal cells much vulnerable to energy failure and necrosis when exposed to inflammatory or other stresses, such as those implicated in AHEM.
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